目的：他汀类药物和睾酮替代疗法 (TTh) 先前已被认为与前列腺癌、结直肠癌和男性乳腺癌（下文中我们将称为激素相关癌症 [HRCa]）和心血管疾病 (CVD) 有关。然而，对于 HRCa 幸存者和匹配的无癌症队列中他汀类药物和 TTh 与 CVD 事件的联合关系知之甚少。方法：我们在 2007-2015 年 SEER-Medicare 中确定了 44,330 名男性，其中 22,165 名之前被诊断患有 HRCa，22,165 名年龄和指数匹配的无癌症患者。本次分析确定了两个匹配队列中 CVD 发生前他汀类药物和 TTh 的诊断前处方。使用加权多变量调整条件逻辑回归模型来评估他汀类药物和 TTh 与 CVD 的独立和组合关联。结果：我们发现他汀类药物（OR = 0.51，95% CI：0.46-0.55）和 TTh（OR = 0.81，95% CI：0.67-0.97）的使用均与整个样本中的 CVD 事件独立呈负相关。 TTh 加他汀类药物也与 CVD 呈负相关。在匹配的无癌症队列中，相关性相似。在 HRCa 幸存者中，只有他汀类药物和 TTh 加他汀类药物联合用药（OR = 0.60，95% CI：0.44-0.98）与 CVD 呈负相关，但单独使用 TTh 与 CVD 无关。结论：一般来说，在 CVD 发生之前，他汀类药物和 TTh 的诊断前使用，无论是单独使用还是联合使用，与总体无癌人群以及 HRCa 幸存者（主要是组合）中的 CVD 呈负相关。他汀类药物和 TTh 的独立作用以及组合仍有待在 HRCa 幸存者中具体 CVD 结局中得到证实。

Purpose : Statins and testosterone replacement therapy (TTh) have been previously linked with prostate, colorectal and male breast cancer (hereinafter we will refer as hormone related cancers [HRCa]), and cardiovascular disease (CVD). However, there is a poor understanding about the combined association of statins and TTh with incident CVD among HRCa survivors and a matched cancer-free cohort. Methods: We identified 44,330 men of whom 22,165 were previously diagnosed with HRCa, and 22,165 were age-and index-matched cancer-free in SEER-Medicare 2007-2015. Pre-diagnostic prescription of statins and TTh prior to CVD development was ascertained for this analysis in the two matched cohorts. Weighted multivariable-adjusted conditional logistic regression models were used to evaluate the independent and combined associations of statins and TTh with CVD. Results: We found that use of statins (OR = 0.51, 95% CI: 0.46-0.55) and TTh (OR = 0.81, 95% CI: 0.67-0.97) were each independently inversely associated with incident CVD in the overall sample. TTh plus statins was also inversely associated with CVD. Associations were similar in the matched cancer-free cohort. Among HRCa survivors, only statins and combination of TTh plus statins (OR = 0.60, 95% CI: 0.44-0.98) were inversely associated with CVD, but the independent use of TTh was not associated with CVD. Conclusion : In general, pre-diagnostic use of statins and TTh, prior to CVD development, independently or in combination, were inversely associated with CVD in the overall, cancer-free population, and among HRCa survivors (mainly combination). Independent effects and combination of statins and TTh remained to be confirmed with specific CVD outcomes among HRCa survivors.